After the U.S., Canada, and Australia, it was turn for Europe, Israel and Japan to approve NeuroSense Therapeutic’s patent application on “Compositions comprising an anti-inflammatory drug and a dicer activator for use in treatment of neuronal diseases.” The patents relate to the formulation of two known FDA (US Food and Drug Administration) approved drugs viz. Ciprofloxacin and Celecoxib in PrimeC to treat Amyotrophic Lateral Sclerosis (ALS). Ciprofloxacin is an antibiotic against bacterial infection, while celecoxib is a prescription non-steroidal anti-inflammatory agent. By regulating microRNA synthesis, this combination drug aims to reduce inflammation of motor neurons affected by ALS and the progression of the disease.
In an earlier pre-clinical study, a zebrafish model of ALS regained swimming abilities after treated with PrimeC as exhibited by improved motor performance and recovered morphology of motor neurons, neuromuscular junction, and microglia. Two clinical trial studies showed the drug to be safe and tolerable with promising clinical signs. Currently, the company is preparing for a robust Phase 2b/3 multinational clinical trial on PrimeC for treatment of ALS.
